Product image of Ioduro (123i) De Sodio Curium Pharma Spain (Sodium Iodide (123 I)) supplied by GNH India

Ioduro (123i) De Sodio Curium Pharma Spain

Active Ingredient:
Sodium Iodide (123 I)
Origin:
EU

Ioduro (123i) De Sodio Curium Pharma Spain (Sodium Iodide (123 I))

Sodium Iodide, the active ingredient in Ioduro (123i) De Sodio Curium Pharma Spain, is a radiopharmaceutical presented as a sterile solution for intravenous use. It is employed in nuclear medicine to visualize thyroid tissue and to assist in the assessment of thyroid‑related disorders.
GNH India supplies Ioduro (123i) De Sodio Curium Pharma Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and nuclear medicine centres worldwide.

Manufacturer / TM Owner

Curium Pharma Spain

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ioduro (123i) De Sodio is used in nuclear medicine for imaging and diagnostic assessment of thyroid and related conditions.

  • Thyroid imaging: enables visualization of thyroid tissue distribution for diagnostic purposes.
  • Thyroid cancer staging: assists in detecting metastatic disease and evaluating disease extent.
  • Radioiodine therapy planning: helps determine the appropriate therapeutic dose by assessing iodine uptake.

How It Works

  • Sodium Iodide (123 I) is taken up by the sodium‑iodide symporter (NIS) expressed on thyroid follicular cells. Once inside the cells, the radionuclide emits gamma photons that are detected by a gamma camera, providing high‑resolution images of thyroid tissue and allowing functional assessment of iodine uptake.

Side Effects

Adverse reactions may occur following intravenous administration of Sodium Iodide (123 I).

Common Side Effects

  • Nausea: mild and transient.
  • Headache: typically low‑intensity.
  • Transient flushing: brief sensation of warmth.
  • Injection site discomfort: mild pain or irritation at the site of administration.

Serious or Rare Side Effects

  • Allergic reaction: rash, itching, or anaphylaxis in susceptible individuals.
  • Radiation‑induced thyroiditis: inflammation of the thyroid gland after exposure.
  • Severe hypotension: marked drop in blood pressure requiring medical attention.

Precautions & Warnings

When using Sodium Iodide (123 I), certain precautions should be observed to ensure patient safety.

  • Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal risk.
  • Breastfeeding: discontinue or avoid unless essential, as radioiodine can be secreted in milk.
  • Renal impairment: monitor renal function because the agent is cleared renally.
  • Thyroid dysfunction: assess baseline thyroid status before administration.
  • Concurrent radioactive iodine therapy: avoid overlapping procedures that could interfere with imaging results.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Sodium Iodide (123 I) may interact with other agents that affect iodine handling or imaging quality.

Major Interactions (Avoid)

  • Other radiopharmaceuticals: simultaneous use can compromise image interpretation.
  • Iodine‑containing contrast agents: may block thyroid uptake and reduce diagnostic accuracy.
  • Thyroid hormone suppressive therapy: can alter iodine distribution and affect results.

Moderate Interactions (Monitor Closely)

  • Diuretics: may modify renal clearance of the agent.
  • Antithyroid drugs (e.g., methimazole): can reduce uptake in thyroid tissue.
  • Beta‑blockers: may influence hemodynamic response during injection.

Frequently Asked Questions

Ioduro (123i) De Sodio contains Sodium Iodide (123 I) and is used in nuclear medicine to image the thyroid gland, assess thyroid cancer spread, and help plan therapeutic radioiodine doses. It provides functional information about iodine uptake in thyroid tissue.

The compound is taken up by the sodium‑iodide symporter on thyroid cells. The radioactive iodine emits gamma photons that are captured by a gamma camera, producing images that reflect the functional activity of the thyroid and any iodine‑avid lesions.

The administered activity is determined by the prescribing physician or nuclear medicine specialist based on the specific diagnostic protocol, patient weight, and clinical indication. Exact dosing is individualized and not standardized in public literature.

Use during pregnancy is only considered when the diagnostic benefit clearly outweighs potential fetal risk. Breastfeeding mothers should avoid the product unless essential, as radioiodine can be secreted in breast milk and expose the infant.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Sodium Iodide (123 I) offers high‑resolution gamma emission suitable for diagnostic imaging, whereas alternatives like Iodine‑131 provide both diagnostic and therapeutic beta emissions but with higher radiation dose. The choice depends on the clinical need for image quality versus therapeutic intent.

The product should be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. It should be kept in the original container until ready for use to maintain stability.

It is administered intravenously by a qualified healthcare professional. The sterile solution is injected into a peripheral vein, and imaging is typically performed shortly after administration to capture the gamma emissions from the thyroid tissue.

Serious risks include allergic reactions that can progress to anaphylaxis, radiation‑induced thyroiditis, and severe hypotension following injection. Patients should be monitored for any signs of these reactions during and after the procedure.

Patients with known hypersensitivity to iodine or sodium iodide, those who have recently received other iodine‑containing radiopharmaceuticals or contrast agents, and individuals in whom the diagnostic benefit does not outweigh the radiation risk should not receive this product.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Iodide (123 I)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT